A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer

Applied Health Economics and Health Policy

Volumn 11, Issue 1, 2013, Pages 27-43

  Jäkel, Anne ^a   Plested, Melanie ^a   Dharamshi, Kuntal ^a   Modha, Rakhee ^a   Bridge, Sarah ^b   Johns, Adam ^b  

^a Heron Evidence Development Ltd   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ERLOTINIB; PEMETREXED;

ADVANCED CANCER; BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HIDDEN MARKOV MODEL; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; QUINAZOLINES; TAXOIDS;

EID: 84873448739     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-012-0001-1     Document Type: Review

References (65)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [online]. http://globocan.iarc.fr/. Accessed 2010 Nov 03.
2. Cancer Research UK. Lung cancer and smoking statistics: key facts [online]. http://www.cancerresearchuk.org/cancer-info/cancerstats/keyfacts/lung- cancer/. Accessed 2010 Nov 05.
3. Cancer Research UK. UK cancer incidence statistics for common cancers [online]. http://info.cancerresearchuk.org/cancerstats/incidence/commoncancers/. Accessed 2009 Feb 01.
4. Chouaid C, Atsou K, Hejblum G, et al. Economics of treatments for non-small cell lung cancer. Pharmacoeconomics. 2009;27(2):113-25.
5. Kutikova L, Bowman L, Chang S, et al. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer. 2005;50(2):143-54.
6. Carlson JJ, Veenstra DL, Ramsey SD. Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs. 2008;68(8):1105-13.
7. Clegg A, Scott DA, Hewitson P, et al. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Thorax. 2002;57(1):20-8.
8. Lyseng-Williamson KA. Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer. Pharmacoeconomics. 2010;28(1):75-92.
9. Waters JS, O'Brien ME. The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE). Br J Cancer. 2002;87(5):481-90.
10. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313(7052):275-83.
11. Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24(4):355-71.
12. Clegg A, Scott DA, Sidhu M, et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Health Technol Assess. 2001;5(32):1-195.
13. Holmes J, Dunlop D, Hemmett L, et al. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer. Pharmacoeconomics. 2004;22(9):581-9.
14. Bhalla S, Hibbert C, Watkins J, et al. To determine the cost-effectiveness of pemetrexed (PEM) compared to current standards of care in 2nd-line advanced non-small cell lung cancer (NSCLC) from the UK National health Service (NHS) perspective [abstract]. J Clin Oncol. 2007;25(18 Suppl):6540.
15. Lewis G, Peake M, Aultman R, et al. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. J Int Med Res. 2010;38(1):9-21.
16. Rutkowski J, Gwiosda B, Lisiecka B, et al. Cost-utility of docetaxel compared with best supportive care and pemetrexed in second line treatment of non-small cell lung cancer in Poland [abstract PCN120]. In: 12th Annual European Congress, ISPOR, 2009 Oct 24-Oct 27, Paris.
17. Capri S, Morabito A, Carillio G, et al. Economic evaluation of erlotinib, docetaxel and pemetrexed as second line treatment in patients with advanced non-small-cell lung cancer (NSCLC): a cost-minimisation in Italian hospitals [abstract PCN36]. Value Health 2007;10 (s1):A333.
18. Asukai Y, Valladares A, Camps C, et al. Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. BMC Cancer. 2010;10:26.
19. Vergnenegre A, Corre R, Berard H, et al. An economical, randomized, multicenter phase III trial of second line treatment for non small cell lung cancer (NSCLC) comparing docetaxel versus pemetrexed: GFPC (Groupe Francnullais De pneumo-cancerologie) 05-06 study [abstract]. Value Health. 2009;12(7):A281.
20. Vergnenegre A, Corre R, Berard H, et al. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study. J Thorac Oncol. 2011;6(1):161-8.
21. Kotowa W, Gatzemeier U, Pirk O, et al. A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective. J Med Econ. 2007;10(3):255-71.
22. Suchankova E, Dolezal T. Cost-minimisation analysis of erlotinib versus docetaxel or pemetrexed as a second-line treatment of advanced non-small lung (NSCLC) in the conditions of the Czech Republic [abstract no. PCN50]. In: 11th Annual European Congress, ISPOR 2008 Nov 9, Athens.
23. Leighl NB, Shepherd FA, Kwong R, et al. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2002;20(5):1344-52.
24. Leighl NB, Shepherd FA, Kwong R, et al. Economic analysis of TAX 317: docetaxel vs. best supportive care (BSC) for second line management of advanced non-small cell lung cancer (NSCLC) [abstract no. 1291]. Proc Am Soc Clin Oncol 2001; 20.
25. Cromwell I, van der Hoek K. MBPS. Erlotinib vs docetaxel as second-line treatment of advanced NSCLC: a real-world cost-effectiveness study [abstract no. P3.036]. In: 14th World conference on lung cancer, 2011 Jul 3-7, Amsterdam.
26. Hsia T, Chang G, Chen Y, et al. Pharmacoeconomic analysis of erlotinib as second-line treatment of advanced non-small cell lung cancer in Taiwan [abstract]. In: 14th European cancer conference, ECCO, 2007 Sept 23-27, Barcelona [J Cancer 2007;5 (4 Suppl):357].
27. Hsia T, Chang G, Chen Y, et al. Cost-effectiveness analysis of erlotinib compared with docetaxel and pemetrexed for second-line treatment of advanced non-small cell lung cancer (NSCLC) in Taiwan [abstract]. In: 10th Annual European Congress, ISPOR; 2007 Oct 20-23, Dublin [Value Health 2007;10 (6):A325].
28. Anaya P, Lopez RJ, Polanco AC. Cost-utility analysis of gefitinib versus docetaxel in a Mexican public institution [abstract]. In: ISPOR 14th annual international meeting; 2009 Oct 24-27, Orlando, FL.
29. Thongprasert S, Permsuwan U. Cost-effectiveness and budget impact analyses of gefitinib in 2nd-line treatment for advanced NSCLC from Thai payer perspective [abstract]. Ann Oncol 2010;21:viii345.
30. Yu YF, Chen ZW, Zhou Z, et al. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China. Chemotherapy. 2010;56(6):472-7.
31. McLeod C, Bagust A, Boland A, et al. Erlotinib for the treatment of relapsed non-small cell lung cancer. Health Technol Assess. 2009;13(Suppl 1):41-7.
32. Rubio-Terres C, Alvarez Sanz C, Gylmark GM. Pharmacoeconomic analysis in Spain of therapy with erlotinib, docetaxel, pemetrexed or best supportive care in patients with advanced non-small cell lung cancer who have failed previous chemotherapy regimens [abstract]. In: 11th Annual European Congress, ISPOR 2008 Nov 8-11, Athens [Value Health 2006 Nov; 9 (6):A283].
33. Araujo A, Parente B, Sotto-Mayor R, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. Rev Port Pneumol. 2008;14(6):803-27.
34. Negreiro F, Pereira C, Pereira H, et al. Economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as 2nd or 3rd line treatment of non-small-cell lung cancer [PCN52]. In: 11th Annual European Congress, ISPOR, 2008 Nov 1, Athens.
35. Pompen M, Novak A, Postmus P, et al. Pharmacoeconomic (PE) analysis of the treatment of non-small cell lung cancer (NSCLC) in the Netherlands demonstrates that erlotinib dominates docetaxel and is cost-effective over best supportive care (BSC) without need for patient stratification [abstract]. In: 9th Annual European Congress, ISPOR 2006 Oct 29-31, Copenhagen [Value Health; 9 (6):A203].
36. Ciuleanu TE, Dediu M, Minea LN, et al. Cost-effectiveness analysis of erlotinib in the treatment of advanced non-small cell lung cancer (NSCLC) in Romania. In: 15th Annual International Meeting, ISPOR; 2010 May 15-19, Atlanta [Value Health; 13 (3):A38].
37. Batigun O, Yildirim E. Pharmacoeconomic analysis of erlotinib compared with docetaxel for the treatment of relapsed non-small-cell lung cancer (NSCLC) in Turkey [abstract]. In: 10th Annual European Congress, ISPOR, 2007 Oct 20-23, Dublin [Value Health; 10 (6):A234].
38. Carlson JJ, Reyes C, Oestreicher N, et al. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer. 2008;61(3):405-15.
39. Horgan AM, Bradbury PA, Amir E, et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. Ann Oncol. 2011;22(8):1805-11.
40. Horgan A, Shepherd F, Bradbury P, et al. Preliminary cost-consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non-small cell lung cancer [abstract 8110]. ASCO Annual Meeting 2008. J Clin Oncol. 2008;26(15 Suppl.):8110.
41. Cromwell I, van der Hoek K, Taylor S, et al. Erlotinib vs best supportive care as third-line treatment of advanced NSCLC: a real-world cost-effectiveness study [abstract no. P3.110]. In: 14th World conference on lung cancer, 2011 Jul 3-7, Amsterdam.
42. Bradbury P, Jang R, Isogai P, et al. A cost utility analysis of erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC) [abstract]. In: 13th Annual international meeting, ISPOR, 2008 May 3-7, Toronto.
43. Bradbury PA, Tu D, Seymour L, et al. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst. 2010;102(5):298-306.
44. Stefani SD, Saggia MG, dos Santos EAV. Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective. J Med Econ. 2008;11(3):383-96.
45. Stefani S, Saggia M, Santos E. Cost-minimisation analysis of erlotinib versus docetaxel or pemetrexed as second-line therapy for non-small cell lung cancer (NSCLC) from the perspective of a private payer in Brazil [abstract PCN32]. In: ISPOR 10th Annual European Congress, 2007 Oct 20-23, Dublin.
46. Santos E, Stefani M, Saggia M. Cost-minimisation analysis of erlotinib versus docetaxel or pemetrexed as second-line therapy for non-small cell lung cancer (NSCLC) from the perspective of a private payer in Brazil according to local HTA guidelines. In: 33rd Annual ESMO Meeting, 2008 Sep 12-16, Stockholm.
47. Pavlakis N, Mitchell PL, Stynes G, et al. Cost-effectiveness of pemetrexed for previously treated advanced non-small cell lung cancer [abstract]. ASCO Annual meeting proceedings: Part I of II. J Clin Oncol. 2005;23(165 Suppl):6084.
48. Kim YG, Lee EK. Cost-effectiveness analysis of erlotinib versus docetaxel as a second-or third-line treatment of non-small cell lung cancer in Korea [abstract]. Value Health. 2010;13(7):A514.
49. National Institute for Health and Clinical Excellence. Pemetrexed for the treatment of non-small cell lung cancer: report no.: TA124. National Institute for Health and Clinical Excellence; 2007.
50. Scottish Medicines Consortium. Erlotinib, 25, 100 and 150 mg film-coated tablets (220/05): NHS Scotland; 2005. Report No.: 220/05.
51. Scottish Medicines Consortium. Erlotinib, 100 and 150 mg film-coated tablets, resubmission (220/05): NHS Scotland; 2006. Report No.: Resubmission 220-05.
52. Scottish Medicines Consortium. Pemetrexed, 500 mg, powder for reconstitution (342/07): NHS Scotland; 2007. Report No.: 342/07.
53. Scottish Medicines Consortium. Pemetrexed, 500 mg vial of powder for solution for intravenous infusion (342/07), first resubmission: NHS Scotland; 2008.
54. Scottish Medicines Consortium. Pemetrexed 500 mg vial of powder for solution for intravenous infusion, second resubmission (342/07): NHS Scotland; 2008.
55. Pharmaceutical Benefits Advisory Committee. Erlotinib hydrochloride, film-coated tablets, 25 mg, 100 mg, 150 mg (base), Tarceva ® : PBAC; 2007 Nov.
56. Pharmaceutical Benefits Advisory Committee. Erlotinib hydrochloride, film-coated tablets, 25 mg, 100 mg, 150 mg (base), Tarceva ® : PBAC; 2006 Nov.
57. Pharmaceutical Benefits Advisory Committee. Erlotinib hydrochloride, film-coated tablets, 25 mg, 100 mg, 150 mg (base), Tarceva ® : PBAC; 2006 March.
58. National Institute for Health and Clinical Excellence. Erlotinib for the treatment of non-small-cell lung cancer: National Institute for Health and Clinical Excellence; 2008 Oct. Report No.: TA162.
59. National Institute for Health and Clinical Excellence. Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal): National Institute for Health and Clinical Excellence; 2009. Report No.: TA175.
60. National Institute for Health and Clinical Excellence. Lung cancer (non-small-cell, second line treatment)-vandetanib (suspended): National Institute for Health and Clinical Excellence; 2008. Report No.: TA Wave19/54.
61. Canadian Coordinating Office for Health Technology Assessment. Erlotinib. Tarceva-Hoffmann-La Roche Limited: CCOHTA; 2005 Dec 6.
62. Canadian Coordinating Office for Health Technology Assessment. Gefitinib 250 mg tablets (Iressa: AstraZeneca): CCOHTA; 2004 Jun 23.
63. Appleby J, Devlin N, Parkin D. NICE's cost effectiveness threshold. BMJ. 2007;335(7616):358-9.
64. Gold M, Siegel J, Russell L. Cost-effectiveness in health and medicine: report of the panel on cost-effectiveness in health and medicine. New York, NY: Oxford University Press; 1996.
65. Mather D, Sullivan SD, Parasuraman TV. Beyond survival: economic analyses of chemotherapy in advanced, inoperable NSCLC. Oncology. 1998;12(2):199-209.